Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
Dean Follmann(National Institute of Allergy and Infectious Diseases), Myron S. Cohen(University of North Carolina at Chapel Hill), Allyson Mateja(Frederick National Laboratory for Cancer Research), David Benkeser(Emory University), Michael P. Fay(National Institutes of Health), Hana M. El Sahly(Baylor College of Medicine), Meagan P. O’Brien(Regeneron (United States)), Jonathan Fintzi(National Institutes of Health), Holly Janes(Fred Hutch Cancer Center), K.-C. Chan(Regeneron (United States)), Flonza Isa(Regeneron (United States)), Jacqueline M. Miller(Moderna Therapeutics (United States)), Youyi Fong(Fred Hutch Cancer Center), Eduardo Forleo‐Neto(Regeneron (United States)), Gary Herman(Regeneron (United States)), Nicole A. Doria‐Rose(National Institutes of Health), Peter B. Gilbert(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Mary Marovich(University of Maryland, Baltimore), Lindsey R. Baden(Brigham and Women's Hospital), Weiping Dang(Moderna Therapeutics (United States)), David C. Montefiori(Duke University), K. C. Turner(Regeneron (United States)), Andrea T. Hooper(Regeneron (United States))
Cited by 44
Related Papers
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k